Study of belzutifan and zanzalintinib for recurrent kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests two new drugs, belzutifan and zanzalintinib, for people with advanced kidney cancer that returned after or within 2 years of finishing an immunotherapy treatment after surgery. You cannot have received any other cancer treatments besides that immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced kidney cancer (Stage IV) that has come back after a prior immunotherapy treatment given after surgery.
- Your cancer must have clear cell features (the most common kidney cancer type).
- You have not had any other treatments for your kidney cancer besides the immunotherapy after surgery.
- You do not have a serious heart condition, lung inflammation, or uncontrolled infections like HIV or hepatitis.
- You must not have had major surgery within the last 8 weeks or have unhealed wounds or fractures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new drug combinations for people with advanced kidney cancer whose disease returned after a prior immunotherapy. It's designed to find better treatment options for those who have not received other treatments for advanced disease.
This Phase 2 study tests a “next-step” cabozantinib strategy for advanced kidney cancer (RCC) after your cancer previously responded to cabozantinib and then progressed. It aims to see if re-using cabozantinib in a planned sequence can control the cancer again with manageable side effects.
This trial tests an experimental drug (HC-7366) combined with an approved targeted therapy (belzutifan) for people with advanced kidney cancer. It aims to see if the combination is safe and works better than either drug alone.
This study tests two new drugs, belzutifan and zanzalintinib, for people with advanced kidney cancer that has not responded well to other treatments. The goal is to see if the combination slows down cancer growth.
This trial tests a new drug combination for people with advanced clear cell kidney cancer that has gotten worse after initial immunotherapy treatment. The goal is to see if adding zanzalintinib to another immunotherapy can help control the cancer.
This trial tests a new drug called zanzalintinib for people with advanced clear cell kidney cancer that has spread to the bones (at least 3 spots). The study wants to see if this drug can help slow down or shrink the cancer. It's for patients who have already had some prior treatments.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.